A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to determine the effect of the study drug, MPDL3280A (a monoclonal antibody) on programmed cell death-1 ligand 1 (PD-L1)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The study also aims to learn more about the safety and tolerability of the study drug.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Atezolizumab
Phase: Phase 2
Ages Eligible For Study:
- Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent non-small cell lung cancer (NSCLC) - PDL1-positive status as determined by an IHC assay performed by a central laboratory - ECOG Performance Status of 0 or 1 - Life expectancy >= 12 weeks - Measurable disease, as defined by RECIST v1.1 - Adequate hematologic and end organ function